Previous Page  3 / 24 Next Page
Information
Show Menu
Previous Page 3 / 24 Next Page
Page Background

Agenda

From preclinical data to the approvals in recurrent ovarian

cancer

Olaparib in front line ovarian cancer

A view to the future